ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2021 - 2025)
ProQR Therapeutics (PRQR) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $131.3 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 26.87% to $131.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $633.9 million through Dec 2025, down 14.62% year-over-year, with the annual reading at $131.3 million for FY2025, 26.87% down from the prior year.
- Liabilities and Shareholders Equity hit $131.3 million in Q4 2025 for ProQR Therapeutics, down from $179.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $239.8 million in Q4 2021 to a low of $131.3 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $174.7 million across 5 years, with a median of $174.8 million in 2022.
- Biggest five-year swings in Liabilities and Shareholders Equity: decreased 27.1% in 2022 and later increased 20.98% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $239.8 million in 2021, then dropped by 27.1% to $174.8 million in 2022, then decreased by 15.12% to $148.4 million in 2023, then increased by 20.98% to $179.5 million in 2024, then decreased by 26.87% to $131.3 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for PRQR at $131.3 million in Q4 2025, $179.5 million in Q4 2024, and $148.4 million in Q4 2023.